ArticleBMC urology2013
Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection.
Article in BMC urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Development and prospective validation of a multitarget urine RNA assay for noninvasive detection of urothelial carcinoma.iScience · 2025Article
- Serum α1-AT Levels andDiseases (Basel, Switzerland) · 2024Article
- Sequential Application and Post-Test Probability for Screening of Bladder Cancer Using Urinary Proteomic Biomarkers: A Review based Probabilistic Analysis.Asian Pacific journal of cancer prevention : APJCP · 2023Review
- Label-free quantitative proteomics reveals aberrant expression levels of LRG, C9, FN, A1AT and AGP1 in the plasma of patients with colorectal cancer.Clinical proteomics · 2023Article
- CCL18 Knockdown Suppresses Cell Growth and Migration in Thyroid Cancer.Journal of healthcare engineering · 2022Article
- Identification of prognostic and therapeutic value of CC chemokines in Urothelial bladder cancer: evidence from comprehensive bioinformatic analysis.BMC urology · 2021Article
- Discovery of bladder cancer biomarkers in paired pre- and postoperative urine samples.Translational andrology and urology · 2021Article
- Influencing Factors on the Oncuria™ Urinalysis Assay: An Experimental Model.Diagnostics (Basel, Switzerland) · 2021Article
- CCL18 in the Progression of Cancer.International journal of molecular sciences · 2020Review
- Discovery of CCL18 antagonist blocking breast cancer metastasis.Clinical & experimental metastasis · 2019Article
- CCL18 enhances migration, invasion and EMT by binding CCR8 in bladder cancer cells.Molecular medicine reports · 2019Article
- Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer.Oncotarget · 2018Article
- The expression of CCL18 in diffuse large B cell lymphoma and its mechanism research.Cancer biomarkers : section A of Disease markers · 2018Article
- Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.Oncogene · 2017Article
- A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer.Bladder cancer (Amsterdam, Netherlands) · 2016Article
- CCL18 promotes the invasion and migration of gastric cancer cells via ERK1/2/NF-κB signaling pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundIn this study, we further investigated the association of two biomarkers, CCL18 and A1AT, with bladder cancer (BCa) and evaluated the influence of potentially confounding factors in an experimental model.
methodsIn a cohort of 308 subjects (102 with BCa), urinary concentrations of CCL18 and A1AT were assessed by enzyme-linked immunosorbent assay (ELISA). In an experimental model, benign or cancerous cells, in addition to blood, were added to urines from healthy controls and analyzed by ELISA. Lastly, immunohistochemical staining for CCL18 and A1AT in human bladder tumors was performed.
resultsMedian urinary protein concentrations of CCL18 (52.84 pg/ml vs. 11.13 pg/ml, p < 0.0001) and A1AT (606.4 ng/ml vs. 120.0 ng/ml, p < 0.0001) were significantly elevated in BCa subjects compared to controls. Furthermore, the addition of whole blood to pooled normal urine resulted in a significant increase in both CCL18 and A1AT. IHC staining of bladder tumors revealed CCL18 immunoreactivity in inflammatory cells only, and there was no significant increase in these immunoreactive cells within benign and cancerous tissue and no association with BCa grade nor stage was noted. A1AT immunoreactivity was observed in the cytoplasm of epithelia cells and intensity of immunostaining increased with tumor grade, but not tumor stage.
conclusionsFurther development of A1AT as a diagnostic biomarker for BCa is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.